American women are largely unaware of uterine fibroid embolization according to results from a new nationwide poll released by the Society of Interventional Radiology (SIR). The data included in the report, “The fibroid fix: What women need to know”, show that 44% of women diagnosed with uterine fibroids say they have never heard of the less invasive treatment option.
At the 2017 Charing Cross Symposium (25–28 April, London, UK), speakers and panellists discussed the challenges of endovascular aortic arch procedures and their potential impact on acute stroke. Looking at both the causes and potential solutions for this problem, those involved noted that while understanding has increased, significant obstructions and risks still remain.
It is well known that women have worse outcomes following treatment for abdominal aortic aneurysms, but a recent study finds that the results are similar for women undergoing TEVAR (thoracic endovascular aneurysm repair) and that gender should be considered in an analysis of risk versus benefit.
iVascular has announced the release of Angiolite BTK, a sirolimus-eluting stent which has received CE mark approval for treating chronic and acute arterial lesions in lower limbs below the knee, improving blood flow in severe claudication and critical limb ischaemia.
Fifty-two-week outcomes of the MOBILE trial indicate a “significant reduction in major amputations” among Rutherford 4 and non-diabetic Rutherford 5 critical limb ischaemia patients following the use of intramuscular injection of autologous bone marrow cells (cBMA).
Avacen is to partner with Morulaa HealthTech of Chennai, India, to introduce its Avacen 100 class II medical device to the country. Initial focus will be to reduce the number of limb amputations resulting from diabetic foot ulcers.
Avinger has announced positive two-year clinical data from the pivotal VISION study of the company’s Lumivascular technology. Twenty-four-month follow-up results from 89 patients were presented by Patrick Muck, chief of Vascular Surgery at Good Samaritan Hospital in Cincinnati, USA, at New Cardiovascular Horizons (NCVH) in New Orleans, USA. This includes an additional 34 patients beyond the interim data set presented on January 25, 2017.
Iliac artery aneurysms—affecting up to one third of patients with complex aortic aneurysms—do not affect all-cause mortality or aneurysm-related mortality in endovascular repair of complex aortic aneurysms, according to a study presented at the 2017 Vascular Annual Meeting (VAM; 30 May–3 June, San Diego, USA).
Biotronik has announced that 12-month data from the BIOFLEX-I study have demonstrated the safety and efficacy of the company’s Pulsar-18 self-expanding stent for blocked superficial femoral artery treatment. The study results were presented during a late-breaking session at the 2017 Complex Cardiovascular Catheter Therapeutics Advanced Endovascular and Coronary Intervention Global Summit (C3; 29–30 June, Orlando, USA).
Cagent Vascular has announced the completion of enrolment in the first-in-human PRELUDE study. The purpose of this prospective, single-arm, multicentre feasibility study is to show the safety and efficacy of the company’s Serranator Alto device used in the superficial femoral artery (SFA) and/or popliteal artery.
Cook Medical is recalling the Zenith Alpha thoracic endovascular graft when used for the treatment of blunt traumatic aortic injury because thrombus may form inside the device after implantation. Cook Medical is also aware of reported cases where the graft became occluded when used to treat such injuries. The thrombosis or occlusion may lead to serious adverse health consequences, including death.
Bard Peripheral Vascular has announced it has received CE marking to market the Covera Plus vascular covered stent.
Fusion imaging can be used for infrarenal endovascular aneurysm repair (EVAR) following a short learning curve with the benefit of lower radiation dose and shorter procedure times, according to a presentation giving at the 2017 Vascular Annual Meeting (VAM; 31 May–3 June, San Diego, USA).
Endologix has announced positive interim results from the LEOPARD (Looking at EVAR outcomes by primary analysis of randomised data) clinical study. LEOPARD is the first and only head-to-head, prospective, multicentre, randomised clinical study comparing currently available endovascular abdominal aortic stent grafts. LEOPARD directly compares the Endologix AFX and AFX2 endografts to other commercially available bifurcated aortic endografts.
Endologix has announced 30-day results from the LUCY (Evaluation of Females who are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair) study. The data showed that at least 28% more women became eligible for minimally-invasive endovascular aneurysm repair (EVAR) when using the company’s Ovation abdominal stent graft system.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos